Correct Answer: C. t(9;22)
The clinical presentation of fever, hepatosplenomegaly, abdominal pain, and markedly elevated WBC count (>50,000/mm³) is pathognomonic for chronic myeloid leukemia (CML), and the genetic hallmark is the Philadelphia chromosome—t(9;22). This translocation results from a reciprocal exchange between the long arms of chromosomes 9 and 22, creating the abnormal BCR-ABL1 fusion gene on chromosome 22. The BCR-ABL1 protein is a constitutively active tyrosine kinase that drives uncontrolled myeloid proliferation, leading to the characteristic leukocytosis and organomegaly from extramedullary hematopoiesis. In Indian populations, CML accounts for 15–20% of all leukemias and typically presents in the chronic phase with the constellation of symptoms described. The t(9;22) is present in ~95% of CML cases and is the diagnostic gold standard. Detection via cytogenetics, FISH, or RT-PCR for BCR-ABL1 transcript is mandatory for diagnosis and guides imatinib mesylate therapy—the standard of care in India per NCCN and Indian hematology guidelines. The massive leukocytosis (often 100,000–500,000/mm³) reflects the myeloid predominance characteristic of CML's chronic phase.
Why the other options are wrong
A. del 3q — Deletion 3q is associated with myelodysplastic syndromes (MDS) and some acute myeloid leukemias, not CML. MDS typically presents with cytopenias and dysplasia rather than massive leukocytosis. This is a trap for students who confuse chromosomal abnormalities across myeloid malignancies without linking the specific cytogenetic finding to the clinical phenotype. B. t(15;17) — The t(15;17) translocation defines acute promyelocytic leukemia (APL/AML-M3), which presents with severe coagulopathy, bleeding, and low WBC counts (often <5,000/mm³), not the marked leukocytosis described. APL is a medical emergency requiring all-trans retinoic acid (ATRA) and arsenic trioxide, not imatinib. NBE uses this to trap students who memorize translocations without understanding their clinical correlates. D. del(1q) — Deletion 1q is seen in multiple myeloma and some lymphoid malignancies, not myeloid leukemias. It does not produce the acute leukocytosis or the specific clinical picture of CML. This option exploits confusion between solid tumor/lymphoid cytogenetics and myeloid leukemia genetics.
High-Yield Facts
- t(9;22) Philadelphia chromosome is present in ~95% of CML cases and is diagnostic; BCR-ABL1 fusion gene drives constitutive tyrosine kinase activity.
- CML chronic phase typically presents with WBC >50,000/mm³, hepatosplenomegaly, and fever; median age at diagnosis in India is 40–50 years.
- Imatinib mesylate is the first-line tyrosine kinase inhibitor (TKI) for CML in India; BCR-ABL1 transcript detection (RT-PCR) is used for minimal residual disease monitoring.
- Blast crisis (acute transformation) occurs in ~5–10% of untreated CML patients; presence of >30% blasts defines progression.
- Cytogenetics vs. FISH vs. RT-PCR: Cytogenetics detects t(9;22) in metaphase; FISH is faster and metaphase-independent; RT-PCR quantifies BCR-ABL1 transcript for treatment response.
Mnemonics
CML Cytogenetics = 9;22 9 = chromosome 9 (ABL gene), 22 = chromosome 22 (BCR gene). Remember: 9 + 22 = 31, but the fusion creates the Philadelphia chromosome (named after the city where it was discovered). Use when you see massive leukocytosis + organomegaly. Acute Leukemia Translocations (Quick Recall) t(15;17) = APL (bleeding, low WBC), t(9;22) = CML (high WBC, splenomegaly), t(8;14) = Burkitt (lymphoma, LDH ↑). Link the number pair to the clinical picture, not just the name.
NBE Trap
NBE pairs massive leukocytosis with multiple cytogenetic abnormalities (del 3q, t(15;17), del 1q) to trap students who memorize translocations without linking them to clinical phenotypes. The key discriminator is the combination of WBC >50,000/mm³ + hepatosplenomegaly, which is CML-specific; t(15;17) causes bleeding and low WBC, not leukocytosis.
Clinical Pearl
In Indian practice, CML is often diagnosed incidentally on routine blood work in asymptomatic patients; however, symptomatic presentation with fever, splenomegaly, and leukostasis-related symptoms (dyspnea, visual disturbances) warrants urgent BCR-ABL1 testing and imatinib initiation to prevent blast crisis and improve long-term survival (>90% at 5 years with TKI therapy).
_Reference: Robbins & Cotran Pathologic Basis of Disease, Ch. 13 (Hematopoietic and Lymphoid Systems); Harrison's Principles of Internal Medicine, Ch. 93 (Chronic Myeloid Leukemia)_